Yiyoung Kwon
YOU?
Author Swipe
View article: Toward personalized therapeutic drug monitoring of ustekinumab in Crohn’s disease: influence of previous exposure to biologics
Toward personalized therapeutic drug monitoring of ustekinumab in Crohn’s disease: influence of previous exposure to biologics Open
Background: Unlike infliximab, ustekinumab (UST) has shown inconsistent associations between drug concentration and clinical efficacy across studies, with varying cutoff therapeutic trough levels (TLs) proposed. Objectives: Given that pati…
View article: Comparison of clinical effectiveness and microbiome impact between specific polymeric and monomeric diet for exclusive enteral nutrition in pediatric Crohn's disease: a prospective cohort study
Comparison of clinical effectiveness and microbiome impact between specific polymeric and monomeric diet for exclusive enteral nutrition in pediatric Crohn's disease: a prospective cohort study Open
Background: According to the ECCO-ESPGHN guideline for the treatment of newly diagnosed pediatric Crohn's disease (CD), exclusive enteral nutrition (EEN) treatment is recommended for inducing remission. This study aimed to compare the clin…
View article: Combining site-specific gut microbiome and mycobiome profiling with clinical indicators for effective management of pediatric Crohn’s disease
Combining site-specific gut microbiome and mycobiome profiling with clinical indicators for effective management of pediatric Crohn’s disease Open
Pediatric-onset Crohn's disease (pCD) is characterized by frequent relapses and long-term impacts on growth, requiring targeted strategies for disease monitoring and treatment. To characterize gut microbiome and mycobiome changes in pCD, w…
View article: Proactive Drug Monitoring Versus Clinically Based Dosing for Endoscopic Healing in Pediatric Crohn’s Disease Receiving Infliximab
Proactive Drug Monitoring Versus Clinically Based Dosing for Endoscopic Healing in Pediatric Crohn’s Disease Receiving Infliximab Open
Dosing based on proactive TDM was superior to clinically based dosing in terms of EH in a randomized controlled trial of pediatric CD. Trial identifier: cris.nih.go.kr: KCT0005190.
View article: Prediction of deep remission through serum TNF-α level at 1 year of treatment in pediatric Crohn’s disease
Prediction of deep remission through serum TNF-α level at 1 year of treatment in pediatric Crohn’s disease Open
A pilot study investigated the cytokine profile (IL-6, TNF-α, IL-17 A, and IL-10) at diagnosis, affecting infliximab (IFX) trough levels (TLs) in pediatric patients with Crohn's disease (CD). In this follow-up study, we evaluated the chang…
View article: Comparison of Endoscopic Healing and Durability between Combination Therapy with Infliximab and Azathioprine versus Infliximab Monotherapy in Pediatric Crohn's disease
Comparison of Endoscopic Healing and Durability between Combination Therapy with Infliximab and Azathioprine versus Infliximab Monotherapy in Pediatric Crohn's disease Open
This study aimed to evaluate endoscopic healing (EH) efficacy and the durability of infliximab (IFX) in combination therapy with IFX and AZA versus IFX monotherapy in pediatric patients with Crohn’s disease (CD). In this retrospective obse…
View article: Long-term outcomes of liver transplantation for biliary atresia and results of policy changes: over 20 years of follow-up experience
Long-term outcomes of liver transplantation for biliary atresia and results of policy changes: over 20 years of follow-up experience Open
Objective Biliary atresia (BA) patients develop chronic liver disease after the Kasai operation and are eventually indicated for liver transplantation (LT). The purposes of this study were to analyze long-term outcomes after LT and risk fa…
View article: Fluorescence-Based Lateral Flow Immunoassay for Quantification of Infliximab: Analytical and Clinical Performance Evaluation
Fluorescence-Based Lateral Flow Immunoassay for Quantification of Infliximab: Analytical and Clinical Performance Evaluation Open
Background: Therapeutic drug monitoring of infliximab (IFX) can improve treatment outcomes; however, the temporal gap between drug concentration monitoring and subsequent availability restricts its practical application. To address this is…
View article: Co-occurrence of leukemia, Crohn’s disease, and tuberous sclerosis in one patient
Co-occurrence of leukemia, Crohn’s disease, and tuberous sclerosis in one patient Open
Leukemia and Crohn’s disease are both diseases that can be influenced by genetic factors. Tuberous sclerosis complex (TSC) is a rare autosomal dominant neurogenetic disorder caused by genetic mutation. This report presents a pediatric case…
View article: Efficacy of Combined Initial Treatment of Methotrexate with Infliximab in Pediatric Crohn’s Disease: A Pilot Study
Efficacy of Combined Initial Treatment of Methotrexate with Infliximab in Pediatric Crohn’s Disease: A Pilot Study Open
Background: The combination of antitumor necrosis factor-alpha (TNF-α) agents with immunomodulators (IMMs) is a common treatment for pediatric Crohn’s disease (CD). Although methotrexate (MTX) can be a first-line medication as an IMM, most…
View article: Impact of the histologic grade of acute gastrointestinal graft-versus-host disease on outcomes in pediatric patients treated with allogeneic hematopoietic stem cell transplantation
Impact of the histologic grade of acute gastrointestinal graft-versus-host disease on outcomes in pediatric patients treated with allogeneic hematopoietic stem cell transplantation Open
Introduction Acute gastrointestinal graft-versus-host disease (GVHD) is a common life-threatening complication after hematopoietic stem cell transplantation (HCT). We aimed to investigate outcomes according to the clinical, endoscopic, and…
View article: Infliximab trough levels are associated with endoscopic healing but not with transmural healing at one year treatment with infliximab in pediatric patients with Crohn’s disease
Infliximab trough levels are associated with endoscopic healing but not with transmural healing at one year treatment with infliximab in pediatric patients with Crohn’s disease Open
Introduction It is well known that infliximab (IFX) trough levels (TLs) are associated with endoscopic healing (EH) in Crohn’s disease (CD). We investigated whether IFX TLs are associated with transmural healing (TH) in pediatric patients …
View article: Dual Biological Therapy for Ulcerative Colitis with Intractable Pyoderma Gangrenosum
Dual Biological Therapy for Ulcerative Colitis with Intractable Pyoderma Gangrenosum Open
Pyoderma gangrenosum is one of the dermatological extra-intestinal manifestations of ulcerative colitis (UC). We report a case of a 26-year-old male patient suffering from relapsed UC with a newly developed pyoderma gangrenosum. His skin a…
View article: Free antibodies-to-infliximab are biomarker for predicting the effect of dose intensification in pediatric Crohn’s disease patients with secondary loss of response
Free antibodies-to-infliximab are biomarker for predicting the effect of dose intensification in pediatric Crohn’s disease patients with secondary loss of response Open
Background: Immunogenicity to antitumor necrosis factor alpha agents, such as infliximab (IFX), may lead to therapeutic failure. Objectives: This study evaluated the relationship between free and total antibodies-to-infliximab (ATIs), trou…
View article: Increased monocyte abundance as a marker for relapse after discontinuation of biologics in inflammatory bowel disease with deep remission
Increased monocyte abundance as a marker for relapse after discontinuation of biologics in inflammatory bowel disease with deep remission Open
Monocytes are involved in the upstream inflammatory process in the immune reaction in inflammatory bowel disease (IBD). Patients with IBD who discontinued biologics have been found to relapse, even after checking for deep remission. This s…
View article: Cytokine Profile at Diagnosis Affecting Trough Concentration of Infliximab in Pediatric Crohn’s Disease
Cytokine Profile at Diagnosis Affecting Trough Concentration of Infliximab in Pediatric Crohn’s Disease Open
Background: This study aims to measure the concentration of cytokines produced during the inflammation process to investigate if there are any differences in response to treatment of pediatric Crohn’s disease and to determine if the initia…
View article: How has the disease course of pediatric ulcerative colitis changed throughout the biologics era? A comparison with the IBSEN study
How has the disease course of pediatric ulcerative colitis changed throughout the biologics era? A comparison with the IBSEN study Open
The incidence of relapse has decreased and the steroid-free period has increased after the introduction of the biological agent. The clinical course also showed a different pattern from that of IBSEN study. The active use of biological age…
View article: Increased Demand for Therapeutic Drugs in Pediatric Ulcerative Colitis Patients With Extraintestinal Manifestations
Increased Demand for Therapeutic Drugs in Pediatric Ulcerative Colitis Patients With Extraintestinal Manifestations Open
Background Ulcerative colitis (UC) is a systemic inflammatory disease with a gut predominance, which may involve other organs. The presence of extraintestinal manifestation (EIM) is an important symptom for clinicians as it alters the trea…
View article: Stratification by Non-invasive Biomarkers of Non-alcoholic Fatty Liver Disease in Children
Stratification by Non-invasive Biomarkers of Non-alcoholic Fatty Liver Disease in Children Open
Background The spectrum of non-alcoholic fatty liver disease (NAFLD) ranges from isolated hepatic steatosis to non-alcoholic steatohepatitis to fibrosis. We aimed to introduce useful biomarkers released during liver inflammation and fibrog…
View article: Comparison of Ustekinumab Trough Concentrations Measured by 2 ELISA Kits and Evaluation of Clinical Response in Crohn’s Disease
Comparison of Ustekinumab Trough Concentrations Measured by 2 ELISA Kits and Evaluation of Clinical Response in Crohn’s Disease Open
Background: Ustekinumab is a recently introduced biological agent for the treatment of Crohn’s disease. The clinical use of the trough concentration of ustekinumab is not as standardized as that of infliximab. The authors aimed to introduc…
View article: Discontinuation of Azathioprine could be considered in pediatric patients with Crohn’s disease who have sustained clinical and deep remission
Discontinuation of Azathioprine could be considered in pediatric patients with Crohn’s disease who have sustained clinical and deep remission Open
Few studies have demonstrated treatment strategies about the duration and cessation of medications in patients with Crohn’s disease (CD). We investigated factors affecting clinical relapse after infliximab (IFX) or azathioprine (AZA) withd…
View article: Vedolizumab Is Safe and Efficacious for the Treatment of Pediatric-Onset Inflammatory Bowel Disease Patients Who Fail a Primary Biologic Agent
Vedolizumab Is Safe and Efficacious for the Treatment of Pediatric-Onset Inflammatory Bowel Disease Patients Who Fail a Primary Biologic Agent Open
VDZ is safe and efficacious for the treatment of pediatric-onset IBD patients failing a primary biologic agent. The durability of VDZ may be enhanced by introducing VDZ earlier in the disease course. Further prospective studies in children…
View article: Needs for Increased Awareness of Gastrointestinal Manifestations in Patients With Human Inborn Errors of Immunity
Needs for Increased Awareness of Gastrointestinal Manifestations in Patients With Human Inborn Errors of Immunity Open
The gastrointestinal (GI) tract is frequently affected by inborn errors of immunity (IEI), and GI manifestations can be present in IEI patients before a diagnosis is confirmed. We aimed to investigate clinical features, endoscopic and hist…
View article: Discontinuation of Azathioprine Could Be Considered in Pediatric Patients with Crohn’s Disease who Have Sustained Clinical and Deep Remission
Discontinuation of Azathioprine Could Be Considered in Pediatric Patients with Crohn’s Disease who Have Sustained Clinical and Deep Remission Open
Few studies have demonstrated treatment strategies about the duration and cessation of medications in patients with Crohn’s disease (CD). We investigated factors affecting clinical relapse after infliximab (IFX) or azathioprine (AZA) withd…
View article: Albumin-to-Globulin Ratio at 1 Year after Anti-Tumor Necrosis Factor α Therapy Can Serve as a Prognostic Biomarker in Pediatric Crohn’s Disease Patients
Albumin-to-Globulin Ratio at 1 Year after Anti-Tumor Necrosis Factor α Therapy Can Serve as a Prognostic Biomarker in Pediatric Crohn’s Disease Patients Open
AGR can be used to predict relapse. Patients with AGRs <1.47 at 1 year after anti-TNF-α therapy are more likely to have low drug TLs and develop ADAs, which increase the possibility of relapse than those with AGRs ≥1.47. Therefore, if the …
View article: COVID-19-related school closing aggravate obesity and glucose intolerance in pediatric patients with obesity
COVID-19-related school closing aggravate obesity and glucose intolerance in pediatric patients with obesity Open
It is important to pay attention to the indirect effects of the social distancing implemented to prevent the spread of coronavirus disease 2019 (COVID-19) pandemic on children and adolescent health. The aim of the present study was to expl…
View article: Therapeutic Lymphatic Embolization in Pediatric Primary Intestinal Lymphangiectasia
Therapeutic Lymphatic Embolization in Pediatric Primary Intestinal Lymphangiectasia Open
Primary intestinal lymphangiectasia (IL) can cause leakage of lymphatic fluids into the gastrointestinal tract, eventually leading to protein-losing enteropathy. A 15-year-old male patient, whose disease began at the age of 8 years, recent…